Belpointe Asset Management LLC bought a new position in shares of Inovio Pharmaceuticals Inc (NASDAQ:INO) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 23,644 shares of the biopharmaceutical company’s stock, valued at approximately $150,000.

A number of other institutional investors also recently bought and sold shares of INO. Teachers Advisors LLC lifted its holdings in Inovio Pharmaceuticals by 2.3% during the first quarter. Teachers Advisors LLC now owns 151,775 shares of the biopharmaceutical company’s stock worth $1,005,000 after buying an additional 3,411 shares during the period. Vanguard Group Inc. lifted its holdings in Inovio Pharmaceuticals by 7.9% during the first quarter. Vanguard Group Inc. now owns 3,098,055 shares of the biopharmaceutical company’s stock worth $20,510,000 after buying an additional 226,861 shares during the period. Schwab Charles Investment Management Inc. lifted its holdings in Inovio Pharmaceuticals by 5.8% during the first quarter. Schwab Charles Investment Management Inc. now owns 305,844 shares of the biopharmaceutical company’s stock worth $2,025,000 after buying an additional 16,845 shares during the period. Bank of America Corp DE lifted its holdings in Inovio Pharmaceuticals by 14.6% during the first quarter. Bank of America Corp DE now owns 28,256 shares of the biopharmaceutical company’s stock worth $188,000 after buying an additional 3,605 shares during the period. Finally, Metropolitan Life Insurance Co. NY lifted its holdings in Inovio Pharmaceuticals by 8.5% during the first quarter. Metropolitan Life Insurance Co. NY now owns 51,573 shares of the biopharmaceutical company’s stock worth $341,000 after buying an additional 4,020 shares during the period. Institutional investors own 32.27% of the company’s stock.

Shares of Inovio Pharmaceuticals Inc (NASDAQ INO) opened at $4.30 on Tuesday. Inovio Pharmaceuticals Inc has a twelve month low of $4.20 and a twelve month high of $9.86.

Inovio Pharmaceuticals (NASDAQ:INO) last issued its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.25) by ($0.15). Inovio Pharmaceuticals had a negative net margin of 221.55% and a negative return on equity of 72.19%. The business had revenue of $2.60 million for the quarter, compared to analysts’ expectations of $10.27 million. During the same quarter in the prior year, the company posted ($0.28) EPS. The business’s revenue for the quarter was down 79.2% on a year-over-year basis. equities research analysts forecast that Inovio Pharmaceuticals Inc will post -1.12 EPS for the current year.

Several analysts have recently commented on INO shares. Citigroup started coverage on Inovio Pharmaceuticals in a report on Wednesday, September 6th. They set a “buy” rating and a $10.00 price objective for the company. BidaskClub upgraded Inovio Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, September 9th. Maxim Group reiterated a “buy” rating and set a $12.00 price objective on shares of Inovio Pharmaceuticals in a report on Tuesday, September 12th. HC Wainwright reiterated a “buy” rating and set a $13.00 price objective on shares of Inovio Pharmaceuticals in a report on Tuesday, September 12th. Finally, Zacks Investment Research lowered Inovio Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, October 10th. Three investment analysts have rated the stock with a sell rating, two have given a hold rating and eight have given a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus target price of $19.16.

WARNING: This story was first posted by Watch List News and is the property of of Watch List News. If you are accessing this story on another publication, it was copied illegally and reposted in violation of international copyright laws. The legal version of this story can be viewed at https://www.watchlistnews.com/belpointe-asset-management-llc-invests-150000-in-inovio-pharmaceuticals-inc-ino-stock/1772380.html.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals, Inc (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company’s DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases.

Want to see what other hedge funds are holding INO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Inovio Pharmaceuticals Inc (NASDAQ:INO).

Institutional Ownership by Quarter for Inovio Pharmaceuticals (NASDAQ:INO)

Receive News & Ratings for Inovio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.